Lung Stent Market Size & Share 2026-2035

Lung Stent Market Size

The global lung stent market was estimated at USD 175.9 million in 2025. The market is expected to grow from USD 191.5 million in 2026 to USD 432.5 million in 2035, at a CAGR of 9.5% during the forecast period, according to the latest report published by Global Market Insights Inc. The market is driven by numerous factors, such as rising prevalence of lung cancer, growing incidence of COPD and post-tuberculosis stenosis, among other factors.

Lung stents, also known as airway stents, are implantable tubular medical devices used to maintain or re‑establish airway patency within the trachea and bronchial passages that become narrowed or obstructed due to pathological or mechanical causes such as malignancies, infections, or traumatic injury. These devices are manufactured using materials including silicone, metallic alloys, or hybrid constructions to meet varying clinical requirements. Lung stents are commonly employed in the management of respiratory conditions such as lung cancer, tracheomalacia, and chronic obstructive pulmonary disease (COPD).

Increasing investments by the public and private organizations for the development of non-vascular stents is expected to fuel the industry's growth. Boston Scientific, COOK GROUP, MERIT MEDICAL, MICRO-TECH ENDOSCOPY, and TaeWoong MEDICAL are among the leading players operating in the market. These players mainly focus on product innovation, geographic expansion, research and development, and collaboration with local or regional healthcare providers, among other factors.

Rising prevalence of lung cancer emerged as a significant growth driver for the lung stent market. According to the World Health Organization, lung cancer was the leading cause of cancer incidence and mortality worldwide, accounting for an estimated 2.5 million new cases and 1.8 million deaths in 2022. A substantial proportion of this burden was considered preventable, with more than 1.3 million cases among men and nearly 500,000 cases among women attributable primarily to tobacco smoking, which accounted for approximately 60–70% of cases, followed by air pollution and occupational exposures. The high incidence of advanced-stage lung cancer resulted in an increased prevalence of airway obstruction caused by tumor growth and disease progression, thereby driving demand for airway management solutions. Consequently, lung stents played a critical role in palliative and interventional respiratory care, supporting airway patency, improving respiratory function, and contributing to improved quality of life in affected patient populations.

Additionally, the growing incidence of chronic obstructive pulmonary disease (COPD) and post‑tuberculosis airway stenosis served as a key demand driver for the market. According to the European Respiratory Society Report 2025, more than 80 million people were affected by COPD across Europe, with a significant proportion of cases remaining undiagnosed, highlighting a substantial unmet clinical need. The progressive nature of COPD, combined with complications arising from prior pulmonary tuberculosis, contributed to increasing cases of airway narrowing, collapse, and fixed stenosis, particularly in advanced disease stages. These conditions often resulted in persistent airflow limitation and recurrent respiratory distress, necessitating interventional airway management. As a result, lung stents were increasingly adopted as an effective therapeutic option to maintain airway patency, relieve obstruction, and improve respiratory function in patients with severe COPD and post‑tuberculosis airway complications, thereby supporting market growth.

Lung Stent Market Trends

• The market is increasingly influenced by a range of emerging technological and strategic trends. One of the most notable developments is the growing adoption of 3D printing technology to produce patient‑specific lung stents, enabling customized solutions for complex airway anatomies and enhancing procedural precision and clinical outcomes. In parallel, biodegradable lung stents are gaining attention due to their ability to reduce long‑term complications associated with permanent implants, including infection risk and device migration.
• Advancements in artificial intelligence (AI) and machine learning (ML) are further transforming the market by improving diagnostic accuracy and procedural planning. AI‑enabled imaging and navigation systems support more precise stent placement, thereby lowering procedural risks and improving patient safety. Additionally, the integration of digital health and remote monitoring platforms is facilitating post‑procedure follow‑up and early intervention, strengthening continuity of care.
• The market is also experiencing increased collaboration between medical device manufacturers and research institutions, aimed at developing next‑generation lung stents with improved durability, flexibility, and biocompatibility. Furthermore, rising investments in emerging economies, supported by expanding healthcare infrastructure and improved access to advanced respiratory interventions, are contributing to broader market expansion. Collectively, these trends underscore a shift toward innovation‑driven growth and enhanced accessibility within the global market.

Lung Stent Market Analysis

Based on product, the lung stent market is segmented into tracheal stents, bronchial stents, and laryngeal stents. The tracheal stents segment accounted for a dominant market share of 69.1% in 2025, driven by the ability of tracheal stents to provide immediate airway patency, strong positional stability, and sustained structural support in complex airway interventions. The segment is expected to reach USD 295 million by 2035, growing at a CAGR of 9.3% during the forecast period.

• The tracheal stents segment constituted the dominating product category in the lung stents market, reflecting their critical role in maintaining patency of the central airway in patients with severe tracheal obstruction or collapse. These stents are extensively utilized in interventional pulmonology procedures to address indications such as malignant airway compression, post‑intubation strictures, and structural airway instability. Ongoing advancements in stent materials, structural design, and deployment techniques continued to support their widespread clinical adoption across hospital and specialty care settings.
• The bronchial stents segment is projected to expand at 9.8% CAGR to reach USD 115.6 million by 2035. The bronchial stents segment was driven by their application in managing obstructions within segmental and lobar bronchi arising from conditions such as advanced malignancies, post‑infectious scarring, and chronic inflammatory airway diseases. These stents are designed to conform to complex bronchial anatomies and are frequently used in minimally invasive bronchoscopic procedures. Continuous innovation focused on improving flexibility, conformability, and placement accuracy supported the integration of bronchial stents into routine airway management practices
• The laryngeal stents segment is projected to expand at 9.6% CAGR to reach USD 21.9 million by 2035. The laryngeal stents segment addressed specialized clinical needs related to maintaining airway patency at the laryngeal level following surgery, trauma, or stenotic conditions. These devices are commonly used in cases requiring temporary structural support while preserving airway function and minimizing the need for extensive surgical intervention. Advancements in biocompatible materials and precision‑guided placement techniques contributed to their adoption within specialized otolaryngology and airway reconstruction procedures.

Based on device type, the lung stent market is segmented into self-expandable and balloon-expandable. The self-expandable segment is projected to expand at 9.6% CAGR to reach USD 341.3 million by 2035.

• The self‑expandable stents segment represented the dominating category in the market, driven by its widespread clinical use in managing complex and dynamic airway obstructions. These stents are designed to conform to variable airway anatomies and exert continuous radial force, allowing effective deployment in irregular or compressed airways. Their flexibility and suitability for minimally invasive bronchoscopic procedures supported consistent adoption in both malignant and benign airway management. Continuous improvements in alloy composition and structural engineering further enhanced deployment accuracy and in‑situ performance.
• The balloon-expandable segment is projected to expand at 9.2% CAGR to reach USD 91.2 million by 2035. The balloon‑expandable stents segment was characterized by its use in applications requiring precise placement and controlled radial expansion. These stents are typically deployed in anatomically stable airway segments where accurate sizing and positional control are critical. Their rigid structural properties enable targeted airway support and predictable expansion profiles during placement. Adoption of balloon‑expandable stents was supported by advancements in balloon catheter technology and their compatibility with image‑guided interventional procedures, particularly in cases demanding high placement precision.

Based on material, the lung stent market is segmented into silicone, metal, and hybrid. The silicone segment is projected to expand at 9.6% CAGR to reach USD 241.2 million by 2035.

• Silicone stents dominated the market, supported by their favorable clinical profile in airway management. Silicone stents are widely used due to their inert nature, high biocompatibility, and ease of removal or repositioning when required. Their smooth surface design helps minimize tissue in‑growth and facilitates secretion clearance, making them suitable for long‑term airway support in both malignant and benign conditions. These characteristics continued to support their routine use in interventional pulmonology across hospital and specialty care settings.
• The metal stents segment is projected to expand at 9.4% CAGR to reach USD 172.7 million by 2035. Metal stents were primarily utilized in cases requiring higher radial strength and sustained airway expansion, particularly in structurally compromised or externally compressed airways. Manufactured from materials such as nitinol or stainless steel, these stents offer strong mechanical support and adaptability to airway contours. Their self‑expanding properties and durability made them a preferred option in select complex clinical scenarios, especially where long‑term airway scaffolding was required with minimal procedural manipulation.
• The hybrid stents segment is projected to expand at 9.1% CAGR to reach USD 18.6 million by 2035. The hybrid stents segment focused on combining the advantages of both silicone and metal materials to optimize clinical performance. These stents are designed to deliver structural reinforcement through a metallic framework while incorporating silicone or polymer coatings to enhance biocompatibility and reduce tissue irritation. Hybrid stents supported evolving clinical preferences for customized airway solutions by offering improved stability, flexibility, and tolerance, particularly in complex or anatomically challenging airway interventions.

Based on patient, the lung stent market is segmented into adult and pediatric. The adult segment is projected to expand at 9.6% CAGR to reach USD 288.3 million by 2035.

• The adult segment represented the dominating category in the market, reflecting the high utilization of airway stents in adult patients undergoing interventional management for malignant and benign airway obstructions. Lung stent usage in this segment was supported by the prevalence of conditions such as lung cancer, tracheal stenosis, chronic obstructive pulmonary disease–related airway collapse, and post‑surgical complications.
• The pediatric segment is projected to expand at 9.2% CAGR to reach USD 144.2 million by 2035. The pediatric segment addressed a distinct set of clinical requirements related to congenital airway abnormalities, post‑infectious stenosis, and trauma‑related airway compromise. Demand within this segment was influenced by the burden of pediatric respiratory infections, particularly tuberculosis. According to the WHO Global Tuberculosis Report, in 2023, approximately 1.25 million children aged 0–14 years globally fell ill with tuberculosis, with nearly 700,000 cases reported, underscoring the continued need for advanced airway management in complex pediatric cases. Lung stents were utilized selectively in this population to maintain airway patency while supporting growth‑appropriate intervention strategies, with ongoing innovation focused on safety, sizing precision, and biocompatibility for pediatric applications.

Based on end use, the lung stent market is segmented into hospitals, ambulatory surgical centers, and other end users. The hospitals segment dominates the market with a revenue of around USD 115.1 million in 2025.

• Hospitals constituted the leading segment within the market, reflecting their central role in the diagnosis and management of complex airway disorders. Lung stent procedures are predominantly performed in hospital settings due to the availability of advanced bronchoscopy suites, multidisciplinary clinical expertise, and intensive care support required for high‑risk patients. The concentration of interventional pulmonology services, oncology care, and post‑procedural monitoring capabilities within hospitals continued to support consistent utilization of lung stents for both elective and emergency airway management.
• The ambulatory surgical centers segment is projected to expand at 10.2% CAGR to reach USD 109 million by 2035. The ambulatory surgical centers segment supported lung stent adoption in select procedures requiring minimally invasive intervention and short recovery periods. These centers increasingly incorporated advanced endoscopic and bronchoscopic capabilities, allowing for efficient procedural workflows and reduced hospital stays. Lung stent deployment in ambulatory settings was facilitated by technological improvements in stent design and delivery systems, enabling safe outpatient management in carefully selected patient populations.
• The other end users segment is projected to expand at 6.3% CAGR to reach USD 35.9 million by 2035. Other end users, including specialty clinics and long‑term care facilities, contributed to market demand through targeted management of chronic and follow‑up airway conditions. These settings primarily supported post‑hospitalization care, routine monitoring, and adjunctive airway management services. Utilization of lung stents across this segment was aligned with coordinated care models and referral‑based treatment pathways, supporting continuity of care in patients with persistent or recurrent airway complications.

North America Lung Stent Market

The North America market accounted for a majority share of 43.1% in 2025 and is anticipated to show notable growth over the forecast period.

• The U.S. market was valued at USD 54.6 million and USD 58.9 million in 2022 and 2023, respectively. The market size reached USD 68.9 million in 2025, growing from USD 63.6 million in 2024, and is anticipated to grow at a CAGR of 8.9% from 2026 to 2035.
• The North America market was primarily driven by the high and sustained incidence of lung cancer in the region, which continued to be a leading cause of cancer‑related mortality. According to the American Cancer Society, approximately 229,410 new lung cancer cases were estimated in the U.S. in 2026, while the disease accounted for about 124,990 deaths, reinforcing its status as one of the deadliest malignancies nationwide. The high prevalence of advanced‑stage lung cancer frequently resulted in malignant airway obstruction, tracheobronchial compression, and stenosis, significantly increasing the demand for interventional pulmonary procedures.
• Furthermore, North America’s advanced healthcare infrastructure and strong adoption of interventional pulmonology techniques further supported lung stent utilization. High clinician awareness, widespread availability of bronchoscopic expertise, and access to innovative stent technologies enabled early intervention and improved procedural outcomes. Moreover, favorable reimbursement frameworks and ongoing investments in respiratory care technologies strengthened market uptake. Consequently, North America maintained a leading position in the global market, underpinned by a large patient pool requiring airway management, continued technological advancements, and an established ecosystem for advanced respiratory therapies.

Europe Lung Stent Market

Europe accounted for a significant share of the global market and was valued at USD 46.8 million in 2025.

• The Europe market was significantly influenced by the sustained burden of lung cancer across key countries in the region, particularly UK. According to Cancer Research UK, around 50,200 new lung cancer cases were diagnosed annually in the UK during 2021-2022, equivalent to nearly 140 new cases per day. Lung cancer was the third most diagnosed cancer in the UK, accounting for approximately 12% of all new cancer cases. The high incidence of lung cancer, coupled with late-stage diagnosis in a substantial proportion of patients, resulted in an increased prevalence of airway obstruction and bronchial stenosis.
• Additionally, Europe’s market benefited from strong adoption of advanced interventional pulmonology practices and the presence of specialized respiratory centers across Western and Northern Europe. Increasing use of minimally invasive bronchoscopic procedures, combined with growing clinician expertise in airway management, facilitated wider acceptance of lung stents for complex airway conditions. In addition, supportive regulatory frameworks, access to innovative stent technologies, and rising investment in respiratory disease management programs reinforced market growth.

Asia Pacific Lung Stent Market

The Asia Pacific market accounted for a substantial share of the market and was valued at USD 38.4 million in 2025.

• The Asia Pacific market was increasingly influenced by rapid demographic aging across the region, which significantly expanded the population at risk for chronic respiratory and airway disorders. According to the United Nations Population Fund (UNFPA), projections indicated that by 2050, one in four people in Asia and the Pacific would be aged over 60 years, with the population of older persons expected to triple between 2010 and 2050, reaching nearly 1.3 billion. This demographic shift heightened the prevalence of age‑associated pulmonary conditions, including malignancies, airway collapse, and post‑infectious stenosis, thereby increasing the need for interventional airway management solutions such as lung stents.
• Additionally, improving access to healthcare services and the gradual expansion of interventional pulmonology capabilities across emerging Asia Pacific economies supported market growth. As aging populations placed greater demand on hospital systems for minimally invasive respiratory interventions, lung stents were increasingly adopted to manage complex airway obstructions and preserve respiratory function in elderly patients. Combined with rising healthcare expenditure, growing medical tourism in select markets, and increasing clinician expertise, these demographic and structural factors positioned Asia Pacific as a high‑growth region within the global market.

Latin America Lung Stent Market

The Latin American market is anticipated to exhibit remarkable growth during the analysis period.

• The Latin America market was increasingly influenced by demographic transitions and the rising burden of age‑related respiratory disorders across the region. According to the National Institutes of Health (NIH), in 2023, Latin America and the Caribbean had an estimated 91.5 million people aged 60 years and older, representing 13.9% of the total population, with this proportion projected to approach nearly 25% by 2050. The expansion of the elderly population contributed to a higher incidence of airway obstruction associated with chronic respiratory diseases, malignancies, and post‑infectious complications, thereby increasing the clinical need for interventional airway solutions such as lung stents.
• Furthermore, the market benefitted from increasing investments by public and private organizations aimed at the development of non‑vascular stents, including airway applications. Governments, research institutes, and medical device manufacturers across Latin America increasingly prioritized innovation in minimally invasive respiratory technologies to address unmet clinical needs and reduce long‑term healthcare costs. These investments supported product development, clinical adoption, and improved availability of advanced lung stent solutions within hospital settings. Collectively, demographic aging and growing institutional investment strengthened the foundation for continued growth of the market across Latin America.

Middle East and Africa Lung Stent Market

The Middle East and Africa market is expected to experience substantial growth over the analysis timeframe.

• The Middle East and Africa (MEA) market was influenced by the rising burden of respiratory disorders, including lung cancer, post‑infectious airway stenosis, and trauma‑related airway obstruction. Persistent exposure to smoking, environmental pollutants, and infectious diseases increased the need for interventional airway management across the region.
• Growth was further supported by expanding healthcare infrastructure and increased investment in advanced respiratory care, particularly in Saudi Arabia and UAE. The development of specialty hospitals and improved access to minimally invasive pulmonary procedures contributed to the gradual adoption of lung stents, positioning the MEA region as an emerging market with steady long‑term growth potential.

Lung Stent Market Share

• The market is highly dynamic, with key players such as Boston Scientific, COOK GROUP, MERIT MEDICAL, MICRO-TECH ENDOSCOPY, and TaeWoong MEDICAL, which collectively account for 65% share of the global market.
• Leading medical device manufacturers in the market derive competitive advantage from well‑established relationships with hospitals, specialty respiratory centers, and interventional pulmonology networks. These companies leverage broad airway management portfolios and integrated procedural solutions encompassing advanced stent designs, delivery systems, and imaging compatibility. Their strategic strength is rooted in the ability to support complex airway interventions through standardized instrumentation, clinician training programs, and optimized procedural workflows, thereby enhancing clinical efficiency and treatment outcomes in high‑acuity care settings.
• Concurrently, emerging and regional manufacturers are strengthening their market presence by offering cost‑effective and application‑specific lung stent solutions tailored to local clinical needs and healthcare budgets. Innovation within the competitive landscape is centered on advancements in material science, including improved biocompatibility, flexibility, and surface engineering, as well as the adoption of customized and next‑generation stent designs. Strategic partnerships, technology collaborations, and targeted mergers and acquisitions continue to play a critical role as market participants seek to expand geographic reach, diversify product offerings, and enhance differentiation within the evolving market.

Lung Stent Market Companies

A few of the prominent players operating in the global lung stent industry include:

• Boston Scientific
• COOK GROUP
• EFER ENDOSCOPY
• ENDO-FLEX
• HEALTH MICROPORT MEDICAL
• HOOD LABORATORIES
• MERIT MEDICAL
• MICRO-TECH ENDOSCOPY
• mi-TECH
• NOVATECH
• Peytant
• Renata Medical
• Standard Sci Tech
• STENING
• TaeWoong MEDICAL
• Teleflex
• Boston Scientific

Boston Scientific holds a leading position in the lung stent market, supported by its long‑standing expertise in interventional pulmonology and a well‑established portfolio of tracheobronchial stents. The company’s airway stent solutions are widely adopted for the management of malignant and benign airway obstructions, particularly in complex hospital‑based procedures. Strong global distribution capabilities, continuous product refinement, and integration with advanced bronchoscopic platforms have reinforced Boston Scientific’s role as a key technology and volume driver in the market.

• Cook Group (Cook Medical)

Cook Group is a prominent participant in the market, recognized for its focus on minimally invasive medical devices and palliative airway solutions. The company’s tracheobronchial stents are commonly used in cases of tumor‑related airway compression where long‑term patency and procedural reliability are critical. Cook Medical’s market presence is strengthened by trusted relationships with physicians, broad clinical application experience, and consistent adoption across tertiary care hospitals and specialty centers.

• Merit Medical

Merit Medical has established a strong position in the lung stent market through its targeted focus on tracheobronchial stent systems and delivery technologies. The company emphasizes design features that support precise placement, stable airway expansion, and procedural efficiency, aligning with the needs of interventional pulmonologists. Merit Medical’s growing footprint in airway stenting reflects continuous portfolio expansion, increased adoption in hospital settings, and strategic emphasis on minimally invasive respiratory interventions.

Lung Stent Industry News

• In October 2024, Peytant obtained U.S. FDA De Novo clearance for its AMStent Tracheobronchial Covered Stent System, an innovative airway stent designed for adult patients with malignant tracheobronchial strictures. The system integrates a minimally invasive catheter‑based delivery platform with an amnion‑derived stent covering intended to minimize stent migration, local inflammatory response, and mucus buildup. This approval underscored regulatory support for novel lung stent technologies aimed at enhancing palliative care outcomes and maintaining airway patency in patients with advanced pulmonary cancers.
• In August 2024, Renata Medical received FDA approval for its Minima Growth Stent, the first device tailored for neonates, infants, and young children with congenital heart defects. Designed to treat aortic coarctation and pulmonary artery stenosis, the stent can expand as children grow, addressing a long-standing need in pediatric cardiology.

The lung stent market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in (USD Million) from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Tracheal stents
• Bronchial stents
• Laryngeal stents

Market, By Device Type

• Self-expandable
• Balloon-expandable

Market, By Material

• Silicone
• Metal
  • Stainless steel
  • Nitinol
• Hybrid

Market, By Patient

• Adult
• Pediatric

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE